Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Ventyx Biosciences, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Ventyx Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 48,560 $ 14,676 $ 83,997 $ 32,085 General and administrative 8,585 5,722 15,700 11,060 Total operating expenses 57,145 20,398 99,697 43,145 Loss from operations Other expense: Interest income Other expense 5 6 79 Total other expense Net loss $ $ $ $ Unrealized gain on marketable securities 352 Foreign currency translation 38 61 Comprehensive loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 58,556,529 50,848,391 58,100,261 50,717,548 Ventyx Biosciences, Inc. Selected Condensed Consolidated Balance S..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Ventyx Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended March 31, 2023 2022 Operating expenses: Research and development $ 35,437 $ 17,409 General and administrative 7,115 5,338 Total operating expenses 42,552 22,747 Loss from operations Other expense: Interest income Other expense 1 117 Total other expense Net loss $ $ Unrealized gain on marketable securities 539 Foreign currency translation 23 42 Comprehensive loss $ $ Net loss per share, basic and diluted $ $ Weighted average common shares outstanding, basic and diluted 57,638,923 50,585,255 Ventyx Biosciences, Inc. Selected Condensed Consolidated Balance Sheet Data March 31, December 31, 2023 2022 Cash, cash equivalents and marketable securities $ 376,915 $ 356,613 Working..." |
|
| 03/23/2023 |
8-K
| Quarterly results|
Docs:
|
"Ventyx Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended December 31, Year ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 30,185 $ 13,824 $ 87,738 $ 58,481 General and administrative 8,386 4,002 25,398 8,666 Total operating expenses 38,571 17,826 113,136 67,147 Loss from operations Other expense: Interest income Other expense 2 51 Interest expense - related party — — — 99 Change in fair value of notes and derivative - related party — — — 11,051 Change in fair value of Series A tranche liability — — — 5,476 Total other expense 16,599 Net loss Deemed dividend — — — Net loss attributable to common shareholders $ $ $ $ Net loss $ $ $ $ Unrealized gain on marketable securities 181 Foreign cu..." |
|
| 08/15/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/23/2022 |
8-K
| Quarterly results |
| 11/17/2021 |
8-K
| Quarterly results |
|
|